Back to search results

Ventilation and Perfusion in Asthmatics Study

This study is looking at how two different asthma medications, Albuterol Sulfate and AIRSUPRA (Albuterol/Budesonide), affect how air moves in and out of your lungs and how blood flows through them. Researchers will use special imaging to see how these medications change your lung function. You might be able to join if you are an adult between 18 and 75 years old, have been diagnosed with asthma, and your asthma is currently being managed with an inhaled steroid medication. The main goal is to see how much regional ventilation (how air moves in specific parts of your lungs) changes 30 minutes after taking Albuterol/Budesonide. The current status of this study is unclear, and it plans to enroll 40 participants.

Study design
This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 40 adult participants.
What's involved
You would attend two study visits. During these visits, you would receive Albuterol Sulfate and Albuterol/Budesonide via an inhaler with a spacer, and imaging will be performed.
Compensation
Not stated in the trial record.
Follow-up
Regional ventilation will be measured at baseline and 30 minutes after budesonide administration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07426458

Ventilation and Perfusion in Asthmatics

Recruiting
PHASE4Ages 18–75InterventionalTreatment
University of Miami
~40 participants
Updated 2026-05-05 on ClinicalTrials.gov
What's tested:Albuterol SulfateAlbuterol-Budesonide

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Regional Ventilation
Measured over Baseline, 30 minutes after budesonide administration

Conditions

Asthma

Explore related trials

Asthma

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Trishul Siddharthan, MD · PRINCIPAL_INVESTIGATOR · University of Miami

Who to contact

Maria McCoy
[email protected]
305-243-2568
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Physician diagnosis of asthma
Baseline Forced Expiratory Volume in 1 Second (FEV1) \< 80% of predicted, with reversibility (10%) on post-bronchodilator spirometry
Adults, 18-75 years of age
Long-term inhaled controller medication consisting of or including an Inhaled corticosteroids (ICS) at a steady dose for at least 3 months before enrollment

Exclusion

Current cigarette smoking or a past history of \>10 pack-year smoking
Current nicotine vaping
Pregnant and breast-feeding women
Respiratory infection within 4 weeks of proposed study date
Forced Expiratory Volume in 1 Second (FEV1) \< 50%
Inhaled corticosteroids (ICS)/fast-acting beta agonist (FABA) intolerance
Use of beta-blockers
Use of systemic glucocorticosteroids or oral methyl-xanthines within 30 days of planned study visit.

What this trial measures

  • Change in Regional VentilationBaseline, 30 minutes after budesonide administration

    Regional ventilation will be measured using functional lung imaging (XV LVAS) before and after inhalation of Albuterol/Budesonide. The outcome will be defined as the change in voxel-wise ventilation distribution from end expiration to peak inspiration, normalized to regional lung volume.